Tourmaline Bio (TRML) Projected to Post Quarterly Earnings on Monday

Tourmaline Bio (NASDAQ:TRML - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.02. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tourmaline Bio Stock Up 5.8 %

Shares of TRML stock traded up $0.85 during trading hours on Wednesday, hitting $15.39. 494,753 shares of the company were exchanged, compared to its average volume of 271,287. Tourmaline Bio has a 1 year low of $11.56 and a 1 year high of $29.79. The firm has a fifty day moving average of $15.36 and a 200 day moving average of $18.95. The firm has a market cap of $395.29 million, a PE ratio of -5.46 and a beta of 2.11.

Wall Street Analyst Weigh In

TRML has been the topic of several research reports. Chardan Capital reaffirmed a "buy" rating and issued a $70.00 target price on shares of Tourmaline Bio in a research report on Monday. HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Tourmaline Bio in a report on Monday. Lifesci Capital assumed coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price target on the stock. Finally, Wedbush boosted their price objective on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $49.33.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.